Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Immuneering
(IMRX)
NASDAQ
:IMRX
IMRX
Immuneering
Overview
Analyst Forecasts
AI Stock Analysis
Popular
Dividends
Earnings
Ownership
Financials
Statistics
New
Technical Analysis
Historical Prices
New
News & Insights
Chart
Drug Pipeline
More
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Immuneering (IMRX) Stock News & Sentiment
Compare
Follow
607
Followers
Premium
Ratings
Immuneering: Phase 2a Strength of Atebimetinib in First-Line Pancreatic Cancer Supports Buy Rating Despite Competitive Overhang
9d ago
IMRX
Premium
Company Announcements
Immuneering Reports Strong Phase 2a Pancreatic Cancer Survival Data
9d ago
8K
IMRX
Premium
Company Announcements
Immuneering Corp. Shines in Positive Earnings Call
2M ago
IMRX
Premium
Ratings
Promising Potential of Immuneering’s Atebimetinib: Analyst Recommends ‘Buy’ Rating
2M ago
IMRX
Premium
Company Announcements
Immuneering Corp. Reports Strong Q3 2025 Progress
2M ago
IMRX
Premium
Pre-Earnings
IMRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
IMRX
Premium
Market News
3 Best Stocks to Buy Now, 11/3/2025, According to Top Analysts
2M ago
CORZ
IMRX
More IMRX News >
IMRX News on the Web
All News
Bearish News
Bullish News
2026-01-14
Why Immuneering Corporation’s (IMRX) Stock Is Up 6.41%
AAII
Neutral
2026-01-08
Immuneering updated 12-month data for atebimetinib 'encouraging,' says Leerink
The Fly
Neutral
2026-01-08
IMRX Reports 12-Month Survival Of 64% In First-Line Pancreatic Cancer Patients; But Stock Plunges
rttnews
Neutral
2026-01-08
Why Immuneering Corporation’s (IMRX) Stock Is Down 33.79%
AAII
Neutral
2025-12-29
All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy
Zacks
Bullish
2025-12-24
Immuneering Prepares To Share 12-Month Survival Data In Pancreatic Cancer Trial
rttnews
Bullish
2025-12-24
Why Immuneering Corporation’s (IMRX) Stock Is Up 5.95%
AAII
Neutral
2025-12-23
Immuneering to Reveal Key 12-Month Survival Results for Pancreatic Cancer Therapy in January 2026
Market Chameleon
Neutral
128
Results | Showing
1
out of
16
News Score - Last 7 Days
Neutral
IMRX
Sector Average
Media Buzz
This Week
1 articles
Weekly Average
2.5 articles
News Sentiment
This Week
50%
Sector Average
57%
See how Bullish or Bearish a stock is based on its recent media coverage.
This score is generated using a formula that combines
Media Buzz
and
News Sentiment
.
Media Coverage Analysis
The historical news coverage of this asset in the last three months.
FAQ
What is IMRX’s Media Buzz Sentiment?
1 articles about IMRX were published this week. In an average week, 2.5 articles are published.
What is IMRX’s weekly average amount of articles?
In an average week, 2.5 articles about IMRX are published.
What is IMRX’s News Sentiment?
50% of articles about IMRX were positive this week, compared to its sector average of 57%.
Healthcare Stocks that are Trending in the News
CAH
Cardinal Health
ALKS
Alkermes
WST
West Pharmaceutical Services
AGEN
Agenus
PEN
Penumbra
Showing the stocks with the most bullish news sentiment over the past week
See the stocks with the most bullish news sentiment in the sector
Upgrade Now
You need to enable JavaScript to run this app.